Neutral nanotransporters

1. A composition comprising:

a hydrophobic modified polynucleotide, wherein the hydrophobic modified polynucleotide comprises an isolated double stranded nucleic acid molecule comprising a guide strand and a passenger strand, wherein the isolated double stranded nucleic acid molecule includes a double stranded region and a single stranded region, wherein the double stranded region is from 8-14 nucleotides long, wherein the single stranded region is at the 3′ end of the guide strand and is 4-12 nucleotides long, wherein the single stranded region contains 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 phosphorothioate modifications, wherein at least 40% of the nucleotides of the isolated double stranded nucleic acid molecule are modified, and wherein a hydrophobic conjugate is attached to the isolated double stranded nucleic acid molecule at the 3′ end of the sense strand, and wherein the isolated double stranded nucleic acid molecule does not form a hairpin;

a neutral fatty mixture comprising at least 20% dioleoylphosphatidylcholine (DOPC) or distearoylphosphatidylcholine (DSPC), and at least 20% sterol; and

optionally a cargo molecule,

wherein the hydrophobic modified polynucleotide and the neutral fatty mixture forms a micelle.

2. The composition of claim 1 , wherein the polynucleotide is RNA.

3. The composition of claim 1 , wherein the neutral fatty mixture comprises at least 25% DOPC or 25% DSPC.

4. The composition of claim 3 , wherein the neutral fatty mixture comprises at least 25% sterol.

5. The composition of claim 1 , wherein the composition includes at least 20% DOPC and at least 20% cholesterol.

6. A method of inducing RNAi in a cell comprising:

contacting a cell with a composition of claim 1 , wherein the polynucleotide has at least a region of sequence correspondence to a target gene and wherein the polynucleotide induces RNAi of mRNA of the target gene.

7. A method of inducing RNAi in a subject in need thereof comprising:

administering to the subject an effective amount for inducing RNAi of mRNA of a target gene, a composition of claim 1 , wherein the polynucleotide has at least a region of sequence correspondence to the target gene.

8. The method of claim 7 , wherein the subject is a human.

9. A method for delivering a polynucleotide to a target tissue of a subject in need thereof, comprising

administering to the subject a composition of claim 1 wherein the composition includes a fatty acid in the neutral fatty mixture or cargo molecule associated with targeting to the target tissue in order to deliver the polynucleotide to the target tissue in an amount effective to deliver the polynucleotide to the target tissue.

10. A method of inducing RNAi in a subject in need thereof comprising:

administering to the subject an effective amount for inducing RNAi of mRNA of a target gene, a composition of claim 1 , wherein the polynucleotide has at least a region of sequence correspondence to the target gene, wherein the step of administering is systemic, intravenous, intraperitoneal, intradermal, topical, intranasal, inhalation, oral, intramucosal or intraocular.

11. The composition of claim 1 , wherein each of the at least 40% of nucleotides independently comprises a chemical modification selected from the group consisting of 2′ d, 2′OMe, 2′F, hydrophobic and phosphorothioate.

12. The composition of claim 1 , wherein the cargo molecule is an intralipid or a nutralipid.

13. The composition of claim 1 , wherein the cargo molecule is a fatty acid mixture containing more than 74% linoleic acid, a fatty acid mixture containing at least 6% of cardiolipin, or a fatty acid mixture containing at least 74% linoleic acid and at least 6% of cardiolipin.

14. The composition of claim 1 , wherein the cargo molecule is a fusogenic lipid.

15. The composition of claim 14 , wherein the fusogenic lipid is DOPE.